List of Excipients in Branded Drug VEOZAH

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Astellas Pharma US Inc	VEOZAH	fezolinetant	0469-2660	CELLULOSE, MICROCRYSTALLINE	2031-04-04
Astellas Pharma US Inc	VEOZAH	fezolinetant	0469-2660	FERRIC OXIDE RED	2031-04-04
Astellas Pharma US Inc	VEOZAH	fezolinetant	0469-2660	HYDROXYPROPYL CELLULOSE	2031-04-04
Astellas Pharma US Inc	VEOZAH	fezolinetant	0469-2660	HYPROMELLOSE 2910	2031-04-04
Astellas Pharma US Inc	VEOZAH	fezolinetant	0469-2660	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE	2031-04-04
Astellas Pharma US Inc	VEOZAH	fezolinetant	0469-2660	MAGNESIUM STEARATE	2031-04-04
Astellas Pharma US Inc	VEOZAH	fezolinetant	0469-2660	MANNITOL	2031-04-04

Last updated: August 13, 2026

Veozah’s excipient strategy is conventional, low-risk and commercially replaceable. The product is a once-daily, immediate-release 45 mg oral tablet containing fezolinetant, with lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and a conventional film coating. The main commercial opportunity is not a novel excipient platform. It is a differentiated generic or lifecycle formulation that improves tolerability, swallowing, adherence, supply resilience or hepatic-risk monitoring while preserving bioequivalence.

VEOZAH Excipient Strategy and Commercial Opportunities

What is Veozah and how is it formulated?

Veozah is the U.S. brand name for fezolinetant, a nonhormonal neurokinin 3 receptor antagonist approved by the FDA on May 12, 2023, for moderate to severe vasomotor symptoms associated with menopause.[1]

The marketed product is a 45 mg immediate-release, film-coated tablet administered once daily. Its formulation uses standard oral-solid-dose excipients rather than a proprietary delivery system.

Veozah formulation profile

Attribute	Veozah profile
Active ingredient	Fezolinetant
Strength	45 mg
Dosage form	Immediate-release film-coated tablet
Route	Oral
Dosing	Once daily
FDA application	NDA 215498
Sponsor	Astellas Pharma US, Inc.
Therapeutic category	Nonhormonal treatment for menopausal vasomotor symptoms
Primary formulation opportunity	Oral-solid-dose differentiation
Biosimilar exposure	None; fezolinetant is a small molecule

The FDA label identifies the following inactive ingredients or excipient classes: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and film-coating components including hypromellose, polyethylene glycol, talc and titanium dioxide.[2]

The formulation is consistent with a standard direct-compression or dry-granulation tablet platform. Lactose and microcrystalline cellulose provide bulk and compressibility. Croscarmellose sodium supports rapid disintegration. Colloidal silicon dioxide improves powder flow, and magnesium stearate provides lubrication. The film coat supports tablet appearance, handling and swallowability.

What excipients protect Veozah’s commercial performance?

No single excipient appears to be the principal source of Veozah’s commercial differentiation. Product performance depends on the interaction between particle properties, tablet hardness, disintegration, dissolution and coating robustness.

Functional role of the key excipients

Excipient	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Low-cost, widely available; creates lactose-free differentiation opportunity
Microcrystalline cellulose	Diluent, binder and compaction aid	Supports robust tablet manufacture
Croscarmellose sodium	Superdisintegrant	Helps maintain immediate-release performance
Colloidal silicon dioxide	Glidant and moisture-management aid	Supports powder flow and manufacturing consistency
Magnesium stearate	Lubricant	Excess use can slow dissolution or weaken tablet bonding
Hypromellose	Film-forming polymer	Supports coating integrity and appearance
Polyethylene glycol	Plasticizer in film coating	Improves coating flexibility
Talc	Anti-tacking and coating aid	Supports coating-line performance
Titanium dioxide	Opacifier and colorant	Provides appearance and light protection

The strongest technical control points are likely to be tablet disintegration, dissolution, lubricant concentration, coating weight and raw-material variability. A generic developer could use the same qualitative excipient classes while changing supplier, grade, particle size, compression conditions and coating system.

What commercial opportunities exist for Veozah excipient reformulation?

The most credible opportunities are incremental oral formulation improvements rather than high-risk delivery technologies.

1. Lactose-free Veozah alternative

The presence of lactose creates a straightforward substitution opportunity. A lactose-free tablet could replace lactose with additional microcrystalline cellulose, mannitol, dibasic calcium phosphate or another established diluent.

A lactose-free formulation could support:

• broader use among patients who avoid lactose;
• simplified positioning for pharmacies and health systems;
• reduced dependence on a single diluent system;
• potential private-label or authorized-generic differentiation.

The regulatory benefit is limited if the product remains an immediate-release tablet with the same strength and comparable dissolution. The developer would still need to establish pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.

2. Smaller or easier-to-swallow tablet

Menopausal patients may have adherence barriers associated with tablet size, dysphagia or pill burden. A higher-density formulation could reduce tablet volume. A mini-tablet, thinner tablet or alternative shape could create a patient-experience advantage without changing the release profile.

A smaller tablet would require control of:

• dose uniformity;
• mechanical strength;
• friability;
• dissolution;
• film-coating coverage;
• packaging stability.

The 45 mg dose is sufficiently modest for tablet-size reduction, although the bulk of the final tablet is determined by excipient selection and compression density rather than active loading alone.

3. Orally disintegrating tablet

An orally disintegrating tablet could support patients who have difficulty swallowing conventional tablets. Mannitol-based ODT systems, crospovidone or optimized croscarmellose grades could produce rapid dispersion in the mouth.

The opportunity is commercially attractive but technically more demanding. Fezolinetant has an extremely bitter active pharmaceutical ingredient profile risk typical of many small molecules, so taste masking would be central. Options include:

• polymeric taste-masking coatings;
• ion-exchange resins;
• lipid-based barriers;
• complexation;
• sweetener and flavor systems;
• multiparticulate ODT structures.

An ODT may qualify for a separate formulation patent if the claims cover a specific taste-masking system, excipient ratio, disintegration threshold or dissolution profile. The commercial value depends on whether the dosage form receives meaningful substitution or prescribing preference.

4. Sprinkle or dispersible formulation

A sprinkle formulation could target patients who cannot swallow tablets but can take medication with soft food. This approach would require data on dose recovery, stability after opening, food compatibility and uniform distribution.

A dispersible tablet or oral granule could be more useful than an ODT if the formulation is intended for broader administration flexibility. The drawback is increased packaging and handling complexity.

5. Improved moisture and stability platform

Excipient selection can reduce moisture sensitivity and improve shelf life. Colloidal silicon dioxide, moisture-barrier film coats, high-barrier blister packaging and desiccant-supported bottles are potential tools.

A commercial formulation could combine:

• low-moisture excipient grades;
• foil-foil blister packaging;
• reduced hygroscopicity;
• a protective coating;
• tighter control of water activity.

This strategy is most relevant if stability-indicating data identify degradation or dissolution drift under high humidity. It can also reduce supply risk where standard excipient grades are subject to regional availability constraints.

What formulation patents could protect a Veozah lifecycle product?

Formulation protection would generally need to claim more than the mere use of standard excipients. A patent based only on lactose, microcrystalline cellulose, croscarmellose sodium and magnesium stearate would face significant obviousness risk unless the formulation produces an unexpected technical result.

Potential claim categories include:

Immediate-release composition claims

These could cover a defined excipient ratio, tablet hardness range, disintegration time, dissolution profile or impurity limit. The strongest claims would connect composition to a measurable performance advantage.

Taste-masked fezolinetant claims

A patent could cover a coated particle, resin complex, polymer matrix or multiparticulate system that reduces bitterness while maintaining rapid release.

ODT claims

Claims could focus on:

• rapid disintegration;
• low friability;
• acceptable mouthfeel;
• specific mannitol or superdisintegrant ratios;
• dissolution within a defined time;
• dose uniformity at reduced tablet weight.

Manufacturing-process claims

Process claims could cover granulation, compression, coating or drying conditions that improve dissolution, content uniformity or stability.

Packaging and stability claims

Packaging patents may protect a moisture-control system, blister architecture or container-closure combination. These claims are generally less powerful than composition claims because competitors may design around them.

The relevant legal distinction is between a patent covering the active ingredient, a patent covering the marketed composition and a patent covering a method of use. A formulation patent can remain commercially important after the basic active-ingredient patent expires, but only if it is listed or otherwise enforceable against the competing product and survives validity and infringement challenges.

What is the Orange Book status and exclusivity timeline for Veozah?

Veozah is approved under NDA 215498 and is subject to FDA Orange Book and exclusivity records applicable to the product.[3]

Key regulatory dates

Event	Date
FDA approval	May 12, 2023
Three-year new clinical investigation exclusivity	Expected to run through May 12, 2026, subject to FDA listing treatment
Earliest conventional ANDA commercial pressure	After applicable exclusivity and patent barriers are cleared
Dosage form	Immediate-release tablet
Generic pathway	ANDA, not biosimilar application

Three-year exclusivity generally blocks FDA approval of an ANDA that relies on the listed drug’s new clinical investigations during the exclusivity period. It does not prevent all competing approvals and does not operate in the same manner as a patent.

Exact generic-entry timing depends on the current Orange Book patent listings, pediatric exclusivity, litigation outcomes and any settlement terms. Paragraph IV challengers can file before patent expiration if they certify that listed patents are invalid, unenforceable or not infringed. A timely Paragraph IV notice can trigger a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions and court developments.[4]

When does Veozah lose exclusivity and face generic entry?

The practical risk window begins with the combination of three-year exclusivity expiry and any listed patent expiry or litigation settlement date. For Veozah, May 2026 is the key regulatory milestone because it marks the expected end of the initial three-year exclusivity period.

A generic company would likely prioritize a conventional 45 mg immediate-release tablet because it offers the lowest development and regulatory complexity. The generic product would seek pharmaceutical equivalence, bioequivalence and therapeutic equivalence to Veozah.

Generic launch scenarios

Scenario	Commercial effect
No Paragraph IV litigation	Entry follows patent and exclusivity clearance
Paragraph IV challenge with no settlement	Potential approval after litigation or statutory stay
Settlement with licensed entry	Delayed entry on an agreed date, potentially with authorized generic terms
Formulation-specific generic	Limited differentiation unless the product has a meaningful delivery advantage
Authorized generic	Accelerates price erosion while preserving branded channel control

An ODT, lactose-free tablet or sprinkle product may obtain separate intellectual-property protection, but those products would not automatically block a conventional generic if they are not required for pharmaceutical equivalence.

Which companies are likely to challenge Veozah?

The most likely challengers are large generic manufacturers with established women’s-health, CNS or specialty-tablet portfolios. Potential participants in the broader competitive field include Teva, Viatris, Sandoz, Sun Pharma, Dr. Reddy’s, Lupin, Amneal and Indian or European contract-development manufacturers.

The relevant signals are:

• a Paragraph IV filing;
• an ANDA litigation complaint;
• an Orange Book patent challenge;
• a tentative FDA approval;
• licensing or settlement disclosures;
• patent assignments involving fezolinetant formulations.

No biosimilar competition is relevant because fezolinetant is a chemically synthesized small molecule. The principal threat is conventional generic substitution.

What patent litigation and settlement risks affect Veozah?

A Veozah patent dispute would likely involve the following issues:

1. Whether a listed patent claims the active ingredient, a pharmaceutical composition or a method of treating vasomotor symptoms.
2. Whether the generic label induces infringement of a patented method of use.
3. Whether the proposed generic formulation falls within composition claims.
4. Whether the patent is valid over prior art involving neurokinin antagonists or standard tablet excipients.
5. Whether a settlement permits an agreed launch date before patent expiry.

Method-of-use patents can be difficult to enforce when the generic label removes a patented indication through a skinny-label strategy. Composition patents are usually more direct because infringement depends on the product’s physical formulation. Manufacturing patents can be harder to detect and enforce unless the patented process is necessary to produce the generic product.

How important are excipients to Veozah’s revenue exposure?

The branded product’s revenue exposure is concentrated in the 45 mg tablet because Veozah currently relies on a single oral strength and dosage form. That concentration creates both risk and opportunity.

Revenue risks

• Generic entry can sharply reduce net price.
• A conventional generic can substitute without reproducing every excipient.
• Payer restrictions can limit branded uptake before patent expiry.
• Liver-monitoring requirements can increase treatment friction.
• Competing nonhormonal therapies can constrain market share.

Commercial opportunities

• Premium-priced ODT or sprinkle presentation;
• lactose-free or low-excipient product;
• adherence packaging linked to liver-test reminders;
• co-packaging with monitoring materials;
• international formulations adapted to local excipient preferences;
• contract manufacturing using dual-source excipient platforms;
• licensing of taste-masking or stability technology.

Excipient innovation will not eliminate generic risk. It can extend the product franchise if the reformulated product creates a clinically visible benefit and gains separate patent, regulatory or commercial protection.

How does Veozah compare with competing menopause therapies?

Product or class	Active ingredient	Dosage form	Excipient opportunity	Competitive issue
Veozah	Fezolinetant	45 mg tablet	ODT, lactose-free, smaller tablet, stability	Liver monitoring and generic timing
Osphena	Ospemifene	Oral tablet	Standard tablet reformulation	Hormonal or estrogenic safety considerations
Duavee	Conjugated estrogens/bazedoxifene	Oral tablet	Combination-tablet optimization	Hormone-related prescribing limits
Estrogen products	Various	Oral, transdermal, vaginal	Adhesion, solubility, local delivery	Established generic competition
OTC supplements	Various	Capsules, tablets, powders	Taste, flow and dose consistency	Variable clinical evidence

Veozah’s nonhormonal mechanism provides commercial differentiation, but its formulation is less differentiated than its pharmacology. This makes excipient and dosage-form innovation a practical route to product-line expansion.

What geographic opportunities exist for Veozah excipients?

The U.S. formulation uses globally available excipients, which supports international manufacturing and licensing. Regional opportunities include:

• lactose-free products for markets with stronger lactose-avoidance preferences;
• smaller tablets for markets with different swallowing or packaging expectations;
• blister packaging where humidity protection is important;
• alternative colorants where titanium dioxide restrictions affect local registration;
• locally sourced excipient grades to reduce import dependency;
• multilingual adherence and liver-monitoring packaging.

A global formulation strategy should preserve dissolution equivalence across excipient suppliers. Changes in lactose grade, microcrystalline cellulose particle size, croscarmellose substitution or magnesium stearate blending time can alter tablet performance.

How strong is the Veozah excipient and formulation estate?

The marketed excipient platform appears technically conventional rather than difficult to reproduce. Its strength is likely to be moderate for manufacturing know-how and low to moderate for composition exclusivity unless Astellas has issued or pending patents covering specific formulation parameters not apparent from the public label.

The strongest defensible opportunities for a competitor are:

1. a clearly differentiated ODT with validated taste masking;
2. a lactose-free tablet with equivalent dissolution and improved patient positioning;
3. a smaller tablet with manufacturing and adherence data;
4. a stability-enhanced package and formulation;
5. a delivery system that supports administration with soft food.

The strongest opportunity for the originator is to patent and commercialize a follow-on dosage form before conventional generic entry becomes established.

Key Takeaways

• Veozah is a 45 mg once-daily immediate-release fezolinetant tablet.
• Its excipient system is conventional and uses lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and standard film-coating materials.
• The most credible formulation opportunities are lactose-free tablets, smaller tablets, ODTs, sprinkle systems and moisture-controlled presentations.
• Three-year FDA exclusivity is expected to reach its principal May 2026 milestone, subject to applicable regulatory records.
• Generic risk is conventional Hatch-Waxman risk, not biosimilar risk.
• A simple excipient substitution is unlikely to create strong patent protection without an unexpected technical result.
• Taste masking, rapid disintegration, stability, tablet-size reduction and administration flexibility offer stronger lifecycle strategies.
• Veozah’s single-strength oral-tablet model creates revenue concentration and makes dosage-form diversification commercially relevant.

FAQs

Can a lactose-free Veozah generic receive FDA approval?

Yes. A generic applicant can use a different excipient system if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality and stability.

Would an ODT version of fezolinetant be automatically substitutable for Veozah?

No. An ODT would generally be a different dosage form and may require separate regulatory treatment. Substitution would depend on FDA product classification and state pharmacy law.

Can excipients reduce fezolinetant liver toxicity?

There is no established basis for assuming that conventional excipients reduce fezolinetant-related liver risk. Excipient selection may improve tolerability or adherence, but it does not replace hepatic monitoring or labeling requirements.

Is Veozah exposed to biosimilar competition?

No. Fezolinetant is a small-molecule drug. Competitive entry would occur through an ANDA or another small-molecule pathway, not through a biosimilar application.

What is the most valuable follow-on formulation for Veozah?

A taste-masked, rapidly disintegrating, lactose-free tablet would offer the broadest combination of patient convenience, excipient differentiation and potential lifecycle protection.

References

1. U.S. Food and Drug Administration. (2023, May 12). FDA approves the first nonhormonal treatment for moderate to severe hot flashes caused by menopause. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonhormonal-treatment-moderate-severe-hot-flashes-caused-menopause

2. U.S. Food and Drug Administration. (2024). Veozah (fezolinetant) prescribing information. Astellas Pharma US, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215498s002lbl.pdf

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j). https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapV-partA-sec355.htm